Expanding recommendations for RSV vaccination
Respiratory syncytial virus (RSV) has been increasingly recognized as a prevalent cause of lower respiratory tract infection (LRTI) among adults in the United States.
Related Articles
The Connection Between Social Security Disability Benefits and Health Coverage Through Medicaid and Medicare | KFF
This analysis examines who was eligible for Medicare and/or Medicaid between 2002 and 2022 because they received disability benefits from one of the country’s Social…
Respiratory Syncytial Virus
Respiratory syncytial virus (RSV) is a common cause of lower respiratory tract infection (LRTI) and is responsible for a high burden of hospital admission and…
Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months
The data from PROMIS-I suggest a clinically important benefit of colistimethate sodium delivered via the I-neb adaptive aerosol delivery system in patients with bronchiectasis and…
Mirtazapine to alleviate severe breathlessness in patients with COPD or interstitial lung diseases (BETTER-B): an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial
Our findings suggested that mirtazapine of doses 15 to 45 mg daily over 56 days does not improve severe breathlessness among patients with COPD or…
Pulmonary Dead Space Monitoring: Identifying Subjects With ARDS at Risk of Developing Right Ventricular Dysfunction
BACKGROUND: ARDS is a highly morbid condition characterized by diffuse pulmonary inflammation, which results in hypoxemic respiratory failure. Approximately 25% of patients with ARDS develop…
Odds for respiratory symptoms in 20s high with smoking before adulthood
Adults aged 28 years faced heightened odds for respiratory symptoms if they began smoking before turning 18 years old, according to a presentation at the…
Dupilumab lowers symptom burden in COPD, type 2 inflammation
At 52 weeks, adults with moderate/severe COPD and type 2 inflammation receiving dupilumab vs. placebo showed more improved symptom scores, according to a poster presented…
Pooled BOREAS, NOTUS analysis: Dupilumab beneficial in COPD with type 2 inflammation
Dupilumab led to improvement and was safe in adults with moderate to severe COPD and type 2 inflammation at week 52, according to a pooled…